Immunic, Inc. (NASDAQ:IMUX) Receives $52.43 Consensus Price Target from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned an average recommendation of “Buy” from the ten research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and three have given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $50.8571.

A number of equities research analysts have recently commented on the company. raised Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Stifel Nicolaus set a $25.00 target price on Immunic and gave the stock a “buy” rating in a research note on Thursday, April 16th. D. Boral Capital cut Immunic from a “buy” rating to a “hold” rating in a research note on Wednesday, April 15th. Wall Street Zen cut Immunic from a “hold” rating to a “sell” rating in a research note on Sunday, April 19th. Finally, Guggenheim assumed coverage on Immunic in a research note on Tuesday, March 24th. They issued a “buy” rating and a $70.00 target price on the stock.

Immunic Stock Down 4.5%

Shares of IMUX stock opened at $12.08 on Tuesday. The stock has a market cap of $164.53 million, a price-to-earnings ratio of -2.16 and a beta of 1.20. The business’s fifty day moving average is $11.43 and its 200 day moving average is $8.64. Immunic has a twelve month low of $5.06 and a twelve month high of $15.10.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.37). Equities research analysts expect that Immunic will post -3.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

A number of institutional investors have recently modified their holdings of IMUX. Nantahala Capital Management LLC bought a new position in shares of Immunic during the fourth quarter valued at $2,337,000. Millennium Management LLC boosted its stake in Immunic by 544.6% in the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock worth $1,825,000 after purchasing an additional 2,888,829 shares during the period. Laurion Capital Management LP grew its holdings in Immunic by 106.3% during the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after buying an additional 2,000,000 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Immunic during the 1st quarter valued at approximately $1,020,000. Finally, Marshall Wace LLP grew its holdings in Immunic by 91.2% during the 4th quarter. Marshall Wace LLP now owns 1,019,983 shares of the company’s stock valued at $541,000 after buying an additional 486,468 shares in the last quarter. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.